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Abstract
Introduction—The correlation of markers of disease severity among brothers with Duchenne or 
Becker muscular dystrophy has implications for clinical guidance and clinical trials.
Methods—Sibling pairs with Duchenne or Becker muscular dystrophy (n = 60) were compared 
for ages when they reached clinical milestones of disease progression, including ceased 
ambulation, scoliosis of ≥ 20°, and development of cardiomyopathy.
Results—The median age at which younger brothers reached each milestone, compared with 
their older brothers ranged from 25 months younger for development of cardiomyopathy to 2 
months older for ceased ambulation. For each additional month of ambulation by the older 
brother, the hazard of ceased ambulation by the younger brother decreased by 4%.
Conclusions—The ages when siblings reach clinical milestones of disease vary widely between 
siblings. However, the time to ceased ambulation for older brothers predicts the time to ceased 
ambulation for their younger brothers.
Keywords
ambulation; Becker muscular dystrophy; cardiomyopathy; Duchenne muscular dystrophy; 
scoliosis; sibling features
Correspondence to: C. Cunniff; ccunniff@peds.arizona.edu. 
HHS Public Access
Author manuscript
Muscle Nerve. Author manuscript; available in PMC 2015 June 26.
Published in final edited form as:













Duchenne and Becker muscular dystrophy (DBMD) may occur in multiple sons within a 
family and is associated with variable manifestations among brothers. Common medical 
complications include loss of ambulation, scoliosis, and cardiomyopathy. The life 
expectancy of boys with DBMD has improved from 14.4 years in the 1960s to 25.3 years in 
the 1990s, as more effective treatments have evolved, particularly the use of corticosteroids 
to preserve muscle function and improved respiratory management to prevent pulmonary 
complications.1,2 With increased life expectancy, more boys will experience complications 
associated with advanced disease, including increased use of mobility aids and treatment for 
scoliosis and cardiomyopathy. The mean ages for onset of these clinical milestones of 
disease progression have been published3–8 and can serve as a rough prognostic guide for 
newly diagnosed individuals.
For families with more than 1 affected son, parents and medical providers may question how 
similar their clinical courses will be. For investigators in DBMD, the similarities and 
differences among siblings may also be important for studying the influence of modifying 
genes or the effects of new treatments on clinical outcomes. The purpose of this report is to 
use data from the Muscular Dystrophy Surveillance Tracking and Research Network (MD 
STARnet), a population-based public health surveillance program, to investigate the degree 
of concordance among siblings with DBMD for age at onset of key clinical milestones of 
disease progression. This information has important implications for prognostic counseling 
and anticipatory guidance in families with multiple affected siblings.
MATERIALS AND METHODS
The MD STARnet is a multi-site, population-based surveillance system that collects 
extensive medical information on boys with DBMD born since January 1, 1982 in Arizona, 
Colorado, Georgia, Iowa, and western New York. MD STARnet collects pertinent and 
available information in patient records from regional neuromuscular clinics, hospitals, 
outpatient clinics, death certificates, hospital discharge databases, and other medical sources. 
The study population includes boys with a clinical diagnosis from a neurologist of Duchenne 
or Becker muscular dystrophy, characteristic signs and symptoms, an elevated creatine 
kinase level, a documented dystrophin mutation, a muscle biopsy demonstrating abnormal 
dystrophin by immunostaining or Western blot, and/or a positive family history of an X-
linked muscular dystrophy. A full description of the MD STARnet methods has been 
published.9 This study was conducted under the approval of human subjects review boards 
of each participating surveillance site. This analysis includes data collected through 
September 2011.
Figure 1 depicts criteria for inclusion in the study population. The MD STARnet population 
includes 874 boys with DBMD. Among this population are 60 families with more than 1 
affected boy. Seven families included 3 or 4 affected boys, from whom 2 were selected for 
inclusion. For sibships with more than 2 affected siblings, we chose the 2 siblings with the 
fewest missing values and included only that pair in analyses of the correlation within pairs 
for each clinical milestone. If multiple siblings had the same number of missing values, the 
oldest was chosen for inclusion. Therefore, our final study cohort includes 120 boys from 60 
families with multiple affected siblings. The median year of birth was 1992 (range, 1982–
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2006), and the median age of study participants at their most recent abstracted medical visit 
was 16.1 years (range, 3.1 to 26.7 years). The median age difference between pairs of 
brothers included in the analysis was 3.1 years (range, 0 to 19 years). Four of the pairs are 
half siblings, and 2 pairs are twins. The zygosity of the twin pairs was not noted in their 
records.
The clinical milestones examined in the study cohort were: (1) ceased ambulation, (2) 
scoliosis of 20° or more, and (3) onset of cardiomyopathy. Onset ages for these milestones 
are reported in years and months. Onset of ceased ambulation was defined as the age when 
the individual ceased walking or used a wheelchair full time. Onset of scoliosis was defined 
as the first date that a spine radiograph demonstrated a Cobb angle of ≥ 20°. The degree of 
curvature was determined from available reports in the medical record and was not 
measured independently by the authors. Onset of cardiomyopathy was defined as the age 
that an echocardiogram first identified a fractional shortening (FS) < 28%, or if a measure of 
FS was not available, an ejection fraction (EF) < 55%. As with scoliosis and ambulation 
measures, cardiac function was determined through information available in medical record 
reports and was not assessed independently. Oral corticosteroid use was examined as a 
potential confounder for each of the outcomes. Boys were defined as corticosteroid users if 
they took this medication for at least 6 months at any time before reaching the clinical 
milestone under consideration.
DBMD is a degenerative disorder in which affected individuals progress from normal 
function to dysfunction over a period of years. In order for a sibling to be considered “at 
risk” for a clinical milestone, he must have reached an age when clinical onset might be 
possible. In this study, the minimum risk age for each milestone condition was defined as 
the youngest documented onset of the condition, as found within the MD STARnet 
population database (n = 874). For our analyses of the relationship of the progression of an 
older sibling’s condition compared with his younger brother’s progression, the younger 
sibling must be at an age when he is at risk for the given condition. Therefore, if the younger 
brother of a sibling pair had not yet reached the minimum risk age for a milestone, the 
sibpair was excluded from all analyses of that milestone.
Descriptive statistics for continuous variables were calculated as medians and ranges and for 
categorical variables as frequencies and percentages. Analysis of variance was used to 
examine whether the age difference between brothers was greater for siblings who were 
discordant than for siblings who were concordant.
Simple correlation coefficients were not calculated, because they would include only sibling 
pairs in which both brothers had experienced the milestone, thus biasing the results toward 
brothers who were more similar (i.e., both have reached the clinical milestone). Instead, we 
used a Cox proportional hazard model to examine the effect of an older sibling’s milestone 
onset age on when his younger sibling reached the same milestone or the maximum age at 
which the younger brother was known to not have reached the milestone. Cox proportional 
hazard model analysis allowed us to also include sibling pairs in which only the older 
brother had experienced the milestone and the younger brother had not. Chronological age 
was measured as a continuous variable, and corticosteroid use was examined as a potential 
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confounder. The starting time for being at risk for a given condition was defined as the 
youngest age at which the milestone was met in the full MD STARnet database (n=874 
males). Because the older brother’s milestone onset age was used as the predictor for the 
Cox proportional hazard analysis, we excluded sibling pairs in which the older brother had 
not yet experienced the milestone. We also tested models that included 1 of 5 additional 
steroid confound variables: (1) the use of corticosteroids for at least 6 months before ceased 
ambulation by the older brother; (2) the use of corticosteroids for at least 6 months before 
ceased ambulation by the younger brother; (3) the duration of corticosteroid use by the older 
brother; (4) duration of corticosteroid use by the younger brother; and (5) a categorical 
variable of whether neither, 1, or both brothers used corticosteroids.
We used Kaplan-Meier survival curves to examine the effect of older brothers reaching 
these milestones on the probability that their younger brothers would follow a similar 
clinical course. The median age when older brothers reached each milestone was used to 
categorize them as “early” or “late,” depending on whether they reached that milestone 
before or after the median age of the analysis sample. The log-rank test was used to 
determine whether the curve for the early group was different significantly from the curve 
for the late group.
RESULTS
Among all 120 siblings, the youngest age when each milestone was reached was 5 years, 5 
months for cardiomyopathy, 7 years, 0 months for ceased ambulation, and 10 years, 4 
months for scoliosis ≥20 °. The minimum risk age for each condition, as determined from 
the full MD STARnet database was 4 years, 9 months for cardiomyopathy, 6 years, 0 
months for ceased ambulation, and 6 years, 8 months for scoliosis, as shown in Table 1. The 
majority of the study population was at least as old as these minimums and, therefore, at 
some risk of progression by the time of their most recently abstracted visit. Of the younger 
brothers, 3 were too young to have developed cardiomyopathy, 8 were too young to have 
ceased ambulation, and 10 were too young to have developed scoliosis.
The number of sibling pairs in which both brothers (concordant progression), 1 brother 
(discordant progression), or neither brother (concordant nonprogression) reached each 
milestone is listed in Table 1. Only those sibling pairs who met minimum risk age for that 
milestone are included. For those sib pairs with concordant progression, the difference 
between a younger sibling’s age at condition onset compared with his older sibling’s age at 
condition onset is listed in Table 2 (median and range).
On average, sibling pairs that were discordant for progression tended to have a greater time 
gap between the siblings’ births. Siblings discordant for ceased ambulation had a 
significantly greater chronological age difference compared with siblings who were 
concordant for progression or concordant for nonprogression (t-
statisticconcordant vs. nonconcordant = 2.75; P = 0.008). The difference in sibling chronological 
age was not significant for pairs concordant or discordant for scoliosis (t-statistic = 1.471; P 
= 0.147) or cardiomyopathy (t-statistic = −0.817, P = 0.417).
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Use of corticosteroids for at least 6 months before condition onset, or, for those who did not 
have onset, 6 months before their most recent visit record was evaluated for its effect on 
concordance. The median start age of steroid treated individuals was 7 years, 3 months, and 
the median duration was 2 years, 5 months. In 21 of the 35 sibling pairs concordant for 
ceased ambulation, neither brother had been treated with corticosteroids for at least 6 
months before ceased ambulation. In 9 of these sib pairs, both siblings had been treated with 
corticosteroids, and in 5 sibling pairs, the older brother had been treated with corticosteroids 
and the younger had not. Among the sibling pairs concordant for ceased ambulation there 
were no pairs in which only the younger brother had been treated with corticosteroids for >6 
months before ceased ambulation. Similarly, neither brother was treated with corticosteroids 
in the majority of the concordant sibling pairs before development of scoliosis (6/9) or 
cardiomyopathy (9/19). Only in a single sibling pair concordant for cardiomyopathy was the 
younger brother treated with corticosteroids for >6 months before the outcome, while the 
older brother was not.
Results of the Cox proportional hazard model are shown in Table 3. Among the 3 clinical 
milestones examined, loss of ambulation was the only milestone for which there was a 
significant correlation between older and younger brothers. For each additional month of 
ambulation by the older brother, the hazard of cessation of ambulation by his younger 
brother decreased by 4%. None of the corticosteroid variables, (1) the use of corticosteroids 
for at least 6 months before the cessation of ambulation by the older brother, (2) the use of 
corticosteroids for at least 6 months before cessation of ambulation by the younger brother, 
(3) the duration of corticosteroid use by the older brother, (4) duration of corticosteroid use 
by the younger brother, or (5) a categorical variable of whether neither, one, or both brothers 
used corticosteroids, was significant.
We focused the Kaplan-Meier analysis on ceased ambulation because of the significant 
correlation between brothers for this clinical milestone by Cox regression. The results of the 
Kaplan-Meier analysis shown in Figure 2 illustrate the relationship between the proportion 
of younger brothers still ambulatory and whether their older brothers ceased ambulation 
early or late. Using the log-rank test, early versus late ceased ambulation for older brothers 
predicts the time to ceased ambulation for their younger brothers (P < 0.001).
The data were examined to determine whether the results of the Cox proportional hazard or 
the Kaplan-Meier analysis were affected by the presence of half siblings in the study 
population or by surveillance bias. The 4 sets of half siblings did not affect the results; when 
the analyses were repeated omitting the half sibling pairs, the results did not change 
significantly. The results did not change significantly after eliminating the 2 twin pairs, 
either.
Surveillance bias would be present if a greater number of medical visits increased the 
likelihood that scoliosis or cardiomyopathy would be detected. The number of visits by each 
sibling in a pair are correlated (Pearson correlation coefficient 0.774, P < 0.001); however, 
an independent samples t-test comparing older brothers with scoliosis to those without 
scoliosis indicates that the number of visits per month of age before the diagnosis of 
scoliosis does not differ from the number of visits per month of those without scoliosis (P = 
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0.453), nor is the number of visits before the diagnosis correlated with the age at diagnosis 
by a Pearson correlation coefficient (P = 0.116). Likewise, an independent samples t-test 
comparing older brothers with cardiomyopathy to those without indicates that the number of 
visits per month of age before the diagnosis of cardiomyopathy does not differ from the 
number of visits per month of those without cardiomyopathy (P = 0.878), nor is the number 
of visits before the diagnosis correlated with the age at diagnosis by a Pearson correlation 
coefficient (P = 0.637).
DISCUSSION
Individuals with single gene disorders may have highly variable clinical features, even 
though they share the same mutation. Because siblings share many of the same modifying 
genes and environmental factors, they are likely to be more phenotypically similar than 
others with the same mutation. In our main analyses, each older sibling was used as a 
predictor for one who has the same DBMD mutation (namely, his younger brother). This 
intrasibling comparison serves to stratify on each individual mutation. If the DBMD 
mutation alone could entirely explain onset age for clinical milestones, the predictive value 
of the older brother’s onset on his younger brother’s onset would indeed be far stronger than 
we observed.
Birnkrant et al.10 analyzed pulmonary and cardiac function in sibling pairs with Duchenne 
and Becker muscular dystrophies and found discordant pulmonary outcome among 3 of 7 
pairs and discordant cardiac outcome in 3 of 6. They concluded that this variation could 
have implications for using genotype information to predict the clinical course of DBMD 
and response to treatments. The observed variability in expression between brothers with the 
same mutation underscores this point. Although the clinical outcome of older brothers 
predicted those of their younger brothers for loss of ambulation, we did not find it to be 
predictive for development of scoliosis or cardiomyopathy in this dataset with the small 
sample sizes for these milestones. Furthermore, there were sibships for which the 
differences in reaching clinical milestones were striking, as much as a 6 year, 9 month 
difference for ceased ambulation, a 3 year 10 month difference for scoliosis ≥ 20°, and an 11 
year 11 month difference for cardiomyopathy. This natural variation in clinical outcome 
among boys with identical dystrophin gene mutations and similar modifying gene profiles 
suggests that trials of therapeutic interventions will likely require a large number of subjects 
to detect a significant effect size.
The wide variation in DBMD expression between siblings with the same mutation may be 
influenced by many factors, including use of different treatments, medical complications 
such as obesity, the presence of modifying genes, and epigenetic effects. Use of oral 
corticosteroids is one such treatment that has been associated with prolonged ambulation 
and may contribute to siblings being more or less similar.11–13 We found no significant 
effect of corticosteroid use on the correlation between brothers’ ages when they reached 
each milestone, although in this dataset the number of siblings being treated with steroids 
was relatively small, limiting the conclusions that can be drawn from the finding. Though 
we were unable to measure the effects of modifying genes, at least 1 previous investigation 
found significant negative effects on both disease progression and response to 
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corticosteroids in boys with a polymorphism in the promoter region of the SPP1 
(osteopontin) gene.14 The authors rightly point out that stratification of clinical trials by 
genotype, including known modifiers, such as the SPP1 polymorphism, may improve 
sensitivity and increase statistical power. From a clinical perspective, analysis of modifier 
genotypes may also improve the accuracy of prognosis estimates and might lead to timelier 
introduction of health surveillance maneuvers and treatments. Variation in clinical outcome 
has also been observed in siblings with substantial differences in expression of genes 
believed to be responsible for control of the cell cycle and other processes such as cellular 
proliferation and differentiation.15 Gene loci that are underexpressed or over-expressed in 
patients with mild phenotypes are potential targets for treatments that alter the expression of 
these genes and result in improved outcomes. Studies of discordant sibling pairs may be 
particularly useful for identifying these candidate genes.
Perhaps the most critical, and certainly the most studied complication of DBMD is the 
progressive loss of independent ambulation. Loss of ambulation has been used to distinguish 
dystrophinopathy phenotypes, with boys who cease to walk before age 13 years being 
classified as having Duchenne muscular dystrophy, those who cease to walk after age 16 
years being classified as Becker muscular dystrophy, and those who cease to walk between 
ages 13 and 16 years having an intermediate phenotype. The median age of cessation usually 
occurs between ages 9 and 11 years for those with the Duchenne phenotype.1,7,11,12 In our 
investigation, among the 35 sibling pairs for which both members had ceased ambulation, 
the median age of ceased ambulation was 10 years, 7 months (95% CI 9.1,12.1), and the age 
when the older brother ceased ambulation was a significant predictor for age ambulation 
ceased for his younger sibling. Among sibships concordant for progression, the median age 
of ceased ambulation for younger brothers was approximately 2 years, 1.5 months later 
among those whose older brothers ceased ambulation late compared with those whose older 
brothers ceased ambulation early. Although brothers ceased ambulation within 1 year, 6 
months of one another in 50% of sibling pairs concordant for ceased ambulation, the 
differences in age at ceased ambulation were substantial for other brothers, as high as 6 
years, 9 months. Nonetheless, these data provide a general estimate of the degree to which 
younger siblings will follow a clinical course that is similar to their older brothers. 
Corticosteroid treatment is associated with improved muscle strength, function, and 
prolonged ambulation11–13 and might be expected to influence concordance if: (1) 1 brother 
uses corticosteroids but the other does not; or (2) there is a difference in duration of 
corticosteroid use between 2 brothers who both use corticosteroids. In this analysis, 
however, we found no significant effect of corticosteroid use on ceased ambulation in either 
circumstance. The reason we did not observe such a treatment effect is most likely the result 
of small numbers of sibling pairs (n = 20) in which 1 or both brothers used corticosteroids.
As postural muscle strength decreases in boys with DMD they develop scoliosis, and it 
advances more rapidly after they cease ambulation.13 Of the 33 sibling pairs who had at 
least 1 sibling progress to scoliosis, only 9 sibling pairs had both who developed scoliosis. 
Among the pairs in which the older brother had progressed (n = 29), the older brothers’ age 
of scoliosis did not predict when this condition appeared in the younger brothers. 
Furthermore, in 27 sibling pairs, neither brother had developed scoliosis, despite the fact that 
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most of the boys had ceased ambulation. These data suggest that additional investigation is 
warranted regarding the relationship between scoliosis and ambulation status, to identify 
possible predisposing and protective factors.
Cardiomyopathy occurs commonly in boys with DBMD, and the great majority show 
echocardiographic signs of dysfunction by age 18 years.16,17 In our study there was a 
median difference of 2 years, 1 month in cardiomyopathy onset between brothers in 19 
sibling pairs who were concordant for development of cardiomyopathy, and the age of 
cardiomyopathy onset in older brothers did not predict age of onset for younger brothers. 
Although an individualized cardiomyopathy surveillance strategy that considers family 
history and mutation type might be desirable, our data suggest that these factors do not 
provide sufficient predictive power to support such a strategy.
One of the primary strengths of this analysis is that it is drawn from a population-based 
sample, rather than a clinical referral population, as are many investigations of rare disease 
populations. In addition, the MD STARnet conducts active case finding and systematic and 
standardized collection of data over time, which ensures that the data are comparable across 
each record. This sample is likely the largest reported sample of siblings with DBMD.
This study also has important limitations to recognize. For many of the sibling pairs, neither 
or only 1 of the siblings has experienced the outcome of interest, which limits conclusions 
that can be drawn regarding similarity in course. Because the survival analyses relied on the 
older brother’s condition onset age as the predictor, it was necessary to exclude pairs in 
which the older brother had not experienced the milestone condition, even though the 
younger brother had. This could potentially bias the results, making the correlation between 
milestone progression appear greater than it is. Only 1 of 36 sibling pairs was excluded for 
this reason from the ceased ambulation survival analysis, thus limiting the potential effect of 
this bias in these results. Three sibling pairs were excluded from the scoliosis analyses and 3 
from cardiomyopathy, analyses with already smaller sample sizes. However, because both 
of these analyses found no significant correlation in sibling’s age of progression, no spurious 
correlations were produced by this bias. It is also important to recognize that improved 
treatment has resulted in improved outcomes over time, so that siblings who are far apart in 
age may have different disease patterns as a result of improved treatment. Examination of 
single treatment factors, such as steroid use, may not capture the collective effects of 
improved treatment over time. Although loss of ambulation may be hastened by a lower 
limb fracture, no study subject experienced one in the 6 months before ceased ambulation. 
Another potential confounding factor for ceased ambulation is obesity; however we were 
unable to assess BMI reliably in this population, because height measurements were 
performed infrequently, particularly in those with limited mobility. And finally, because the 
MD STARnet obtains data from existing medical records, the information available for 
analysis is necessarily limited to what is recorded in those records.
In conclusion, there is substantial variability in the age when younger brothers reach clinical 
milestones, compared with their older brothers: from 2 years, 3 months earlier to 3 years, 10 
months later for scoliosis, 6 years, 9 months earlier to 3 years, 11 months later for ceased 
ambulation, and 11 years, 11 months earlier to 7 years, 5 months later for cardiomyopathy. 
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Such differences suggest that the age at which an older sibling reached a milestone is often 
not helpful for anticipating whether or at what age a younger sibling will reach that same 
milestone. As a general trend, however, the age at which older brothers ceased ambulation 
predicted the age when their younger brothers also reached that milestone. For each 
additional month of ambulation by the older brother, the hazard of ceased ambulation by the 
younger brother decreased by 4%. These results have implications for trials of therapeutic 
interventions in DBMD and suggest that large numbers of subjects will likely need to be 
enrolled to detect significant benefits.
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Study population flow chart.
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Kaplan-Meier survival analysis demonstrating the relationship between the proportion of 
younger brothers still ambulatory and whether the older brother ceased ambulation early or 
late. Probability of younger siblings still being ambulatory by age (years) and when the older 
brother has ceased ambulation is P < 0.001. Solid line, older brother ceased ambulation after 
the median age of cessation; broken line, older brother ceased ambulation before the median 
age of cessation; vertical lines, censoring.
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Table 2
Concordant progression in sibling pairs: Difference in younger sibling’s age at clinical milestone onset 
compared to older sibling’s age of onset (in years, months).
Clinical milestone N (pairs)
Median age difference for onset (years, 
months) Minimum (years, months) Maximum (years, months)
Loss of ambulation 35 0, 2 −6, 9 3, 11
Scoliosis ≥ 20° 9 −0, 8 −2, 3 3, 10
Cardiomyopathy onset 19 −2, 1 −11, 11 7, 5
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